NCT05560373

The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Wanbangde Pharmaceutical Group Co., LTD · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Under the premise of basic treatment, to explore the improvement effect of huperzine A injection on short-term and long-term neurocognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage after interventional/surgical treatment.

Detailed description

Description: This is a randomized, controlled, single center, exploratory clinical trial. The subjects are divided into surgical treatment group and interventional treatment group. Each group is divided into test group and control group. The test group is given huperzine A injection (0.2mg/dose) every day, intramuscular injection, for a total of 8 days, and basic treatment is given at the same time; The control group was given basic treatment, and did not receive other neurotrophic drugs except basic drugs. This clinical trial is to evaluate the effect of huperzine A injection on the improvement of postoperative cognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage.

Conditions

• Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage

Interventions

Type	Name	Description
DRUG	Huperzine A injection, operational treatment, the best basic treatment	intramuscular
OTHER	operational treatment, the best basic treatment	other
DRUG	Huperzine A injection, interventional treatment, the best basic treatment	intramuscular
OTHER	Interventional treatment, the best basic treatment	other

Timeline

• Start date: 2022-09-30
• Primary completion: 2024-09-30
• Completion: 2024-09-30
• First posted: 2022-09-29
• Last updated: 2022-09-29

Locations

1 site across 1 country: China